Down 57%, Is AbCellera Biologics a Buy on the Dip?

Wall Street analysts say this drug developer can more than double your money.Discovering new drugs can be a lucrative endeavor, but things aren't working out lately for AbCellera Biologics (ABCL -0.29%). Shares of this unusual biotech stock are down by about 57% from the high water mark they set last summer.The steep losses might seem surprising if you've been paying attention to Wall Street analysts who follow AbCellera Biologics. KeyBanc has an overweight rating on the stock and a $7 per share price targe ...